cilomilast has been researched along with Asthma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bray-French, K; Hersperger, R; Mazzoni, L; Müller, T | 1 |
| Jabaris, SS; Kodimuthali, A; Pal, M | 1 |
| Huang, L; Jiang, HL; Lai, KF; Li, XS; Luo, ZH; Shan, WJ; Zhou, Q | 1 |
| Giembycz, MA | 1 |
| Dai, YR; Xia, XD; Xu, ZJ | 1 |
| Wang, ZL | 1 |
| Fan Chung, K | 1 |
| Abraham, WM; Claveau, D; Dias, R; Dubé, D; Gallant, M; Girard, Y; Goetghebeur, P; Huang, Z; Jones, T; Lacombe, P; Laliberte, F; Liu, S; Macdonald, D; Mancini, JA; Ng, K; Nicholson, DW; Otu, F; Styhler, A; Turner, MJ; Young, RN; Zhang, L | 1 |
| Aksoy, MO; Ji, R; Kelsen, SG; Li, XX; Reddy, PJ; Yang, Y | 1 |
| Barnette, MS; Christensen, SB; Compton, CH; Griswold, DE; Murdoch, RD; Nieman, RB; Torphy, TJ; Underwood, DC | 1 |
6 review(s) available for cilomilast and Asthma
| Article | Year |
|---|---|
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.
Topics: Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Interactions; Humans; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2002 |
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridines | 2004 |
Research on airway inflammation: present status in Mainland China.
Topics: Animals; Asthma; Cyclohexanecarboxylic Acids; Cytokines; Eosinophils; Genetic Therapy; Humans; Inflammation; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Nitriles; Quinolines; Signal Transduction | 2005 |
Phosphodiesterase inhibitors in airways disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Aminopyridines; Animals; Anti-Inflammatory Agents; Asthma; Benzamides; Carboxylic Acids; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 7; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Isoenzymes; Nitriles; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Disease, Chronic Obstructive | 2006 |
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.
Topics: Asthma; Cyclohexanecarboxylic Acids; Drug Approval; Humans; Lung Diseases, Obstructive; Nitriles; Phosphodiesterase Inhibitors | 1999 |
4 other study(ies) available for cilomilast and Asthma
| Article | Year |
|---|---|
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Asthmatic Agents; Asthma; Benzoates; Bronchoalveolar Lavage Fluid; Catalysis; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Enzyme Inhibitors; Eosinophils; Humans; In Vitro Techniques; Male; Naphthyridines; Palladium; Rats; Respiratory Burst; Structure-Activity Relationship | 2000 |
Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Drug Design; Guinea Pigs; Inhibitory Concentration 50; Molecular Structure; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Trachea | 2012 |
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Apoenzymes; Ascaris suum; Asthma; Benzamides; Bronchoconstriction; Carboxylic Acids; Cognition Disorders; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Interferon-gamma; Male; Molecular Structure; Nitriles; Ovalbumin; Polymerase Chain Reaction; Quinolines; Rats; Sensitivity and Specificity; Sheep | 2007 |
Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Carboxylic Acids; Cells, Cultured; Chemokine CXCL10; Cyclohexanecarboxylic Acids; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Gene Expression; Humans; Interleukin-8; Nitriles; Phosphodiesterase Inhibitors; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA; Salmeterol Xinafoate | 2008 |